HNWAG
CRNX icon

High Net Worth Advisory Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

High Net Worth Advisory Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-1,500
Closed -$27.4K – 265
2022
Q4 		$27.4K Sell
1,500
-500
-25% -$8.81K 0.01% 395
2022
Q3 		$39K Buy
+2,000
New +$40.8K 0.02% 364

Other funds holding CRNX

DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

High Net Worth Advisory Group's CRNX Position: Q1 2023 in Review

High Net Worth Advisory Group sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2023, closing a stake of 1,500 shares — an estimated $27.4K sold.

High Net Worth Advisory Group first reported a position in CRNX in Q3 2022 and held it in 2 quarters. The position peaked at $39K in Q3 2022. 128 funds tracked by Wall St. Rank hold CRNX as of Q1 2023.

  • High Net Worth Advisory Group reported no remaining Crinetics Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • High Net Worth Advisory Group sold 1,500 Crinetics Pharmaceuticals shares in Q1 2023, an estimated $27.4K.
  • High Net Worth Advisory Group first reported a position in Crinetics Pharmaceuticals in Q3 2022 and held it in 2 quarters.
  • High Net Worth Advisory Group's Crinetics Pharmaceuticals position peaked at $39K in Q3 2022.
  • 128 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2023.

Based on High Net Worth Advisory Group's 13F filing for Q1 2023, filed 20 Apr 2023.